Teva Pharmaceutical (TEV) Stock Forecast & Price Target

Compare

36 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TEV Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Teva

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TEV Stock 12 Month Forecast

Average Price Target

€34.13

▲(17.68% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Teva Pharmaceutical in the last 3 months. The average price target is €34.13 with a high forecast of €38.16 and a low forecast of €32.22. The average price target represents a 17.68% change from the last price of €29.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"€12","39":"€39","18.75":"€18.75","25.5":"€25.5","32.25":"€32.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38.1561912,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€38.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.12859324,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€34.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.22078368,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€32.22</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,18.75,25.5,32.25,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30,30.627399323076922,31.254798646153848,31.88219796923077,32.509597292307696,33.13699661538462,33.76439593846154,34.39179526153846,35.019194584615384,35.646593907692306,36.273993230769236,36.90139255384616,37.52879187692308,{"y":38.1561912,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30,30.317584095384614,30.63516819076923,30.952752286153846,31.270336381538463,31.587920476923077,31.90550457230769,32.22308866769231,32.54067276307693,32.85825685846154,33.175840953846155,33.49342504923077,33.81100914461538,{"y":34.12859324,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30,30.170829513846154,30.34165902769231,30.51248854153846,30.683318055384614,30.85414756923077,31.024977083076923,31.195806596923074,31.366636110769228,31.537465624615383,31.708295138461537,31.879124652307688,32.049954166153846,{"y":32.22078368,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.1,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€38.16

Average Price Target€34.13

Lowest Price Target€32.22

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Amsellem

Piper Sandler

€33.77

Buy

16.46%

Upside

Reiterated

02/18/26

Teva Pharmaceutical (TEVA) Receives a Buy from Piper Sandler

Les Sulewski

Truist Financial

€32.09→€35.46

Buy

22.29%

Upside

Reiterated

02/18/26

Truist Financial Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

Louise Chen

Scotiabank

€33.77

Buy

16.46%

Upside

Reiterated

02/18/26

Scotiabank Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

Jason Gerberry

Bank of America Securities

€31.24→€32.09

Buy

10.64%

Upside

Reiterated

02/17/26

Teva Buy Rating Reinforced by Strong TL1a Phase 2 Data and $3 Billion Duvakitug Peak Sales Outlook

Matthew Dellatorre

Goldman Sachs

€30.4→€38

Buy

31.02%

Upside

Reiterated

02/10/26

Goldman Sachs Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

Ashwani Verma

UBS

€31.24→€32.93

Buy

13.55%

Upside

Reiterated

01/30/26

UBS Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

Glen Santangelo

Barclays

€29.55→€32.09

Buy

10.64%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD), Waters (NYSE: WAT) and Teva Pharmaceutical (NYSE: TEVA)

Chris Schott

J.P. Morgan

Buy

―

Reiterated

01/11/26

Dennis Ding

Jefferies

€24.49→€33.77

Buy

16.46%

Upside

Reiterated

01/06/26

Teva price target raised, named a top 2026 idea at JefferiesTeva price target raised, named a top 2026 idea at Jefferies

Umer Raffat

Evercore ISI

Buy

―

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Teva Pharmaceutical (NYSE: TEVA)

Yatin Suneja

Guggenheim

Hold

―

Reiterated

11/18/25

Analysts Conflicted on These Healthcare Names: Teva Pharmaceutical (NYSE: TEVA) and Purple Biotech (NASDAQ: PPBT)

Rajesh Kumar

HSBC

€20.26→€16.89

Buy

-41.77%

Downside

Reiterated

04/28/25

Teva price target lowered to $20 from $24 at HSBCTeva price target lowered to $20 from $24 at HSBC

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Amsellem

Piper Sandler

€33.77

Buy

16.46%

Upside

Reiterated

02/18/26

Teva Pharmaceutical (TEVA) Receives a Buy from Piper Sandler

Les Sulewski

Truist Financial

€32.09→€35.46

Buy

22.29%

Upside

Reiterated

02/18/26

Truist Financial Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

Louise Chen

Scotiabank

€33.77

Buy

16.46%

Upside

Reiterated

02/18/26

Scotiabank Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

Jason Gerberry

Bank of America Securities

€31.24→€32.09

Buy

10.64%

Upside

Reiterated

02/17/26

Teva Buy Rating Reinforced by Strong TL1a Phase 2 Data and $3 Billion Duvakitug Peak Sales Outlook

Matthew Dellatorre

Goldman Sachs

€30.4→€38

Buy

31.02%

Upside

Reiterated

02/10/26

Goldman Sachs Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

Ashwani Verma

UBS

€31.24→€32.93

Buy

13.55%

Upside

Reiterated

01/30/26

UBS Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

Glen Santangelo

Barclays

€29.55→€32.09

Buy

10.64%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD), Waters (NYSE: WAT) and Teva Pharmaceutical (NYSE: TEVA)

Chris Schott

J.P. Morgan

Buy

―

Reiterated

01/11/26

Dennis Ding

Jefferies

€24.49→€33.77

Buy

16.46%

Upside

Reiterated

01/06/26

Teva price target raised, named a top 2026 idea at JefferiesTeva price target raised, named a top 2026 idea at Jefferies

Umer Raffat

Evercore ISI

Buy

―

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Teva Pharmaceutical (NYSE: TEVA)

Yatin Suneja

Guggenheim

Hold

―

Reiterated

11/18/25

Analysts Conflicted on These Healthcare Names: Teva Pharmaceutical (NYSE: TEVA) and Purple Biotech (NASDAQ: PPBT)

Rajesh Kumar

HSBC

€20.26→€16.89

Buy

-41.77%

Downside

Reiterated

04/28/25

Teva price target lowered to $20 from $24 at HSBCTeva price target lowered to $20 from $24 at HSBC

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Teva Pharmaceutical

3 Months

xxx

Success Rate

14/19 ratings generated profit

Average Return

+9.63%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +9.63% per trade.

1 Year

Ashwani VermaUBS

Success Rate

17/19 ratings generated profit

Average Return

+43.18%

a rating ―

Copying Ashwani Verma's trades and holding each position for 1 Year would result in 89.47% of your transactions generating a profit, with an average return of +43.18% per trade.

2 Years

xxx

Success Rate

19/19 ratings generated profit

Average Return

+97.14%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +97.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TEV Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TEV has received 30 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TEV average Analyst price target in the past 3 months is 34.13.

Each month's total comprises the sum of three months' worth of ratings.

TEV Financial Forecast

TEV Earnings Forecast

Next quarter’s earnings estimate for TEV is €0.46 with a range of €0.40 to €0.57. The previous quarter’s EPS was €0.81. TEV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year TEV has Performed in-line its overall industry.

TEV Sales Forecast

Next quarter’s sales forecast for TEV is €3.27B with a range of €3.11B to €3.43B. The previous quarter’s sales results were €4.01B. TEV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year TEV has Performed in-line its overall industry.

TEV Stock Forecast FAQ

What is DE:TEV’s average 12-month price target, according to analysts?

Based on analyst ratings, Teva Pharmaceutical Industries Limited’s 12-month average price target is 34.13.

What is DE:TEV’s upside potential, based on the analysts’ average price target?

Teva Pharmaceutical Industries Limited has 17.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Teva Pharmaceutical Industries Limited a Buy, Sell or Hold?

Teva Pharmaceutical Industries Limited has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Teva Pharmaceutical Industries Limited’s share price target?

The average share price target for Teva Pharmaceutical Industries Limited is 34.13. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €38.16 ,and the lowest forecast is €32.22. The average share price target represents 17.68% Increase from the current price of €29.

What do analysts say about Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of Teva Pharmaceutical Industries Limited?

To buy shares of DE:TEV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Teva Pharmaceutical (TEV) Stock Forecast & Price Target

TEV Analyst Ratings

TEV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Teva Pharmaceutical

TEV Analyst Recommendation Trends

TEV Financial Forecast

TEV Earnings Forecast

TEV Sales Forecast

TEV Stock Forecast FAQ

Detailed List of Analyst Forecasts